JP7252758B2 - ヒト及び/又は動物における免疫応答を調節及び/又は刺激するための組成物及び方法 - Google Patents
ヒト及び/又は動物における免疫応答を調節及び/又は刺激するための組成物及び方法 Download PDFInfo
- Publication number
- JP7252758B2 JP7252758B2 JP2018500382A JP2018500382A JP7252758B2 JP 7252758 B2 JP7252758 B2 JP 7252758B2 JP 2018500382 A JP2018500382 A JP 2018500382A JP 2018500382 A JP2018500382 A JP 2018500382A JP 7252758 B2 JP7252758 B2 JP 7252758B2
- Authority
- JP
- Japan
- Prior art keywords
- wall polysaccharide
- composition
- species
- total weight
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 132
- 241001465754 Metazoa Species 0.000 title claims description 89
- 230000028993 immune response Effects 0.000 title claims description 18
- 230000004936 stimulating effect Effects 0.000 title claims description 7
- 238000000034 method Methods 0.000 title description 23
- 150000004676 glycans Chemical class 0.000 claims description 218
- 229920001282 polysaccharide Polymers 0.000 claims description 215
- 239000005017 polysaccharide Substances 0.000 claims description 215
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 126
- 241000235646 Cyberlindnera jadinii Species 0.000 claims description 69
- 238000011282 treatment Methods 0.000 claims description 61
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 56
- 210000002421 cell wall Anatomy 0.000 claims description 54
- 230000012010 growth Effects 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 229920002498 Beta-glucan Polymers 0.000 claims description 10
- 206010012735 Diarrhoea Diseases 0.000 claims description 10
- 230000002538 fungal effect Effects 0.000 claims description 9
- 230000003843 mucus production Effects 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 241000235648 Pichia Species 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 3
- 230000007413 intestinal health Effects 0.000 claims description 3
- 230000004207 intestinal integrity Effects 0.000 claims description 3
- 206010061217 Infestation Diseases 0.000 claims description 2
- 241000235061 Pichia sp. Species 0.000 claims description 2
- 241001360199 Torulaspora sp. Species 0.000 claims description 2
- 244000000021 enteric pathogen Species 0.000 claims description 2
- 150000003272 mannan oligosaccharides Chemical class 0.000 claims description 2
- 230000031990 negative regulation of inflammatory response Effects 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 241001030160 Hanseniaspora sp. Species 0.000 claims 1
- 241000170280 Kluyveromyces sp. Species 0.000 claims 1
- 241000235088 Saccharomyces sp. Species 0.000 claims 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 78
- 235000005911 diet Nutrition 0.000 description 63
- 230000037213 diet Effects 0.000 description 61
- 235000019688 fish Nutrition 0.000 description 46
- 241000238557 Decapoda Species 0.000 description 42
- 241000251468 Actinopterygii Species 0.000 description 40
- 230000001936 parietal effect Effects 0.000 description 31
- 230000037396 body weight Effects 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 22
- 230000004083 survival effect Effects 0.000 description 22
- 210000001616 monocyte Anatomy 0.000 description 20
- 208000015181 infectious disease Diseases 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 239000003642 reactive oxygen metabolite Substances 0.000 description 18
- 230000000977 initiatory effect Effects 0.000 description 17
- 241000271566 Aves Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 15
- 229920001543 Laminarin Polymers 0.000 description 15
- 239000005717 Laminarin Substances 0.000 description 15
- 241000723298 Dicentrarchus labrax Species 0.000 description 14
- 241000277275 Oncorhynchus mykiss Species 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 235000019786 weight gain Nutrition 0.000 description 14
- 230000004584 weight gain Effects 0.000 description 14
- 241000287828 Gallus gallus Species 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 10
- 108010025838 dectin 1 Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 210000000110 microvilli Anatomy 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000007619 statistical method Methods 0.000 description 10
- 230000008642 heat stress Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 239000003674 animal food additive Substances 0.000 description 8
- 235000020940 control diet Nutrition 0.000 description 8
- 238000013401 experimental design Methods 0.000 description 8
- 241000223934 Eimeria maxima Species 0.000 description 7
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 230000000366 juvenile effect Effects 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 206010028851 Necrosis Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000003097 mucus Anatomy 0.000 description 6
- 244000045947 parasite Species 0.000 description 6
- 210000005253 yeast cell Anatomy 0.000 description 6
- 241000223931 Eimeria acervulina Species 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 210000003250 oocyst Anatomy 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 102000007863 pattern recognition receptors Human genes 0.000 description 5
- 108010089193 pattern recognition receptors Proteins 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000010902 straw Substances 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241001265687 Taura syndrome virus Species 0.000 description 4
- 238000010162 Tukey test Methods 0.000 description 4
- 241000696962 White spot syndrome virus Species 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000001974 tryptic soy broth Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 241000223924 Eimeria Species 0.000 description 3
- 241000223932 Eimeria tenella Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 3
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 3
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 235000006486 human diet Nutrition 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 230000000384 rearing effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000003495 Coccidiosis Diseases 0.000 description 2
- 241001126836 Enterocytozoon Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241001149669 Hanseniaspora Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010023076 Isosporiasis Diseases 0.000 description 2
- 241000235649 Kluyveromyces Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 241000277263 Salmo Species 0.000 description 2
- 239000012163 TRI reagent Substances 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000003975 animal breeding Methods 0.000 description 2
- 230000001165 anti-coccidial effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012864 cross contamination Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001739 density measurement Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000021045 dietary change Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 102000027596 immune receptors Human genes 0.000 description 2
- 108091008915 immune receptors Proteins 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 230000003903 intestinal lesions Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 235000021195 test diet Nutrition 0.000 description 2
- 230000008646 thermal stress Effects 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 102000002086 C-type lectin-like Human genes 0.000 description 1
- 108050009406 C-type lectin-like Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241001539217 Enterocytozoon hepatopenaei Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- -1 IL-1beta Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 241000238553 Litopenaeus vannamei Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001123674 Metschnikowia Species 0.000 description 1
- 241000243190 Microsporidia Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000238550 Penaeidae Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 241000170293 Starmerella sp. Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 241000235006 Torulaspora Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000013564 activation of immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010059297 beta-glucan receptor Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000005024 intraepithelial lymphocyte Anatomy 0.000 description 1
- 201000001091 isolated ectopia lentis Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000005122 simple epithelium Anatomy 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Insects & Arthropods (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
C型レクチン受容体デクチン1は、サッカロマイセス・セレビシエ由来のベータ―グルカンと結合し、特に食作用及びザイモサン、サッカロマイセス・セレビシエ由来の細胞壁抽出物等の粒子やサッカロマイセス・セレビシエ系統由来の他の酵母誘導体(他の酵母誘導体は限定されないが、酵母細胞壁、不活性酵母又は自己消化酵母)の除去を導く様々な経路の誘導に関与することが記載されている(Marakalaら、Mamm Genome (2011) 22:55-65)。脅威を検出する機構及び感染に対する迅速な応答は高度に保存されており、免疫応答はこの病原体リガンドの、例えばベータ―グルカンの、宿主細胞の表面上のPRRへの結合によって部分的に引き起こされる。炎症に関連して、数時間以内に、非特異的自然免疫系が活性化される。局所炎症は、感染に対するこの迅速な応答に重要な役割を果たしている。自然免疫系における多くのプレーヤーは、好中球、単球、マクロファージ、補体因子、サイトカイン、抗微生物ペプチド及び急性期タンパク質を含めて、複雑で非常に調節された応答で素早く起動して、感染に対して迅速に防御する。最近では、前記経路を通じた免疫応答の刺激を謳った非特異的で不活性な酵母を基礎とする製品に対する市場選択肢が存在している。しかしながら、これらの製品は特異性及び成果の点で一貫性に欠いている。動物又はヒトの免疫応答の刺激を増強する改善された酵母製品を提供することは非常に望ましいことである。
サッカロマイセス・セレビシエ菌株:L60、L62、L69、L72
カンジダ・ユチリス菌株:L75(NRRL-900)
様々なアッセイで試験した菌体壁多糖のレベル:
カンジダ・ユチリス菌株:菌体壁多糖レベルは、組成物の総重量を基準として30乾燥重量%に標準化した。
サッカロマイセス・セレビシエ菌株:菌体壁多糖レベルは、組成物の総重量を基準として30、35、45、及び60乾燥重量%に標準化した。
カンジダ・ユチリス及びサッカロマイセス・セレビシエの組み合わせ:多糖レベルは、組成物の総重量を基準として30、35、45、及び50乾燥重量%に標準化した。これら組み合わせ中のカンジダ・ユチリスに由来する菌体壁多糖のレベルは、それぞれ、組成物の総重量を基準として15、15、10、15、及び5乾燥重量%、又は組成物中の菌体壁多糖の総重量を基準として50、43、25、33、及び10乾燥重量%だった(図4a及び4b)。
・カンジダ・ユチリスNRRL-900に由来する菌体壁多糖を6乾燥重量%(組成物の総重量を基準として、又は組成物中の菌体壁多糖の総重量を基準として12乾燥重量%)含有する50SC/CU菌体壁多糖:3用量を試験した:飼料中0.04%、0.08%、0.12%。
・S.セレビシエの1つの菌株(CNCM I 1079)に由来する60SC菌体壁多糖を、飼料中0.12%で試験した。
・T-1:対照-酵母誘導体を含まない通常食餌
・T-2:0.08%の50SC/CU菌体壁多糖で補完された対照食餌
・各飼養段階の開始時及び終了時の1檻当たりの体重、
・第2飼養段階の1檻当たりの飼料消費量
・死亡率及び淘汰率
・動物の総数:開始時129匹、終了時125匹。
・性別:雄
・血統:フリージアン(由来:フランスの異なる農場)
T0として:製品を一切含まない対照食餌。
T1:50SC/CU菌体壁多糖で補完した同じ食餌
・最初の2週間:5g/動物/日=2.7g/kgの開始飼料
・その後:3g/動物/日=1.6g/kgの開始飼料
・到着日~2週間:2×1.5L/日の初乳ミルク希釈液(25%CP及び19.5%脂肪)、その後代用ミルク(22%CP及び18%脂肪)+固形飼料(粉末ミール)自由摂取+ストロー自由摂取+水自由摂取。
・2週間~離乳(34日):1×2L/日の代用ミルク(19%CP及び15%脂肪)+固形飼料(粉末ミール)自由摂取+ストロー自由摂取+水自由摂取。
・離乳~出荷:固形飼料(粉末ミール)自由摂取+ストロー自由摂取+水自由摂取
・体重:個々、実験の開始時及び終了時及び食餌変更時。
・飼料摂取量:1檻当たり。食餌変更時に、供給した飼料と変更した日に残っていた飼料の差として。
・罹患率:定期的な集団単位の予防を含む、個体及び集団単位の医療行為。
・死亡率:日付、体重、及び考えられる理由。
・下痢:1檻当たり。下痢発生の日常的点検。
Yjk=μ+axIBW+バッチj+処置k+バッチj*処置k+ejk
・離乳後の食餌に50SC/CU PARIETAL POLYSACCHARIDESを添加することにより、限定的な薬物処方を伴う対照食餌と比べて、最終体重、全体の平均1日増体量、及び全体飼料要求率が数値的な向上する。
・この影響は、恐らくは農場での健康状態に応じて、プレ開始期間よりも開始期間でより大きいと思われる。
・50SC/CU PARIETAL POLYSACCHARIDESは、開始段階中のZnO及び/又は抗生物質の良好で有望な代用物である可能性がある。
50SC/CU PARIETAL POLYSACCHARIDES処置を陽性対照と比較して、50SC/CU PARIETAL POLYSACCHARIDESが抗生物質の代わりになる可能性を試験すること、及び抗生物質に加えて50SC/CU PARIETAL POLYSACCHARIDESを添加することが及ぼす補完的効果の可能性を試験することが推奨される。
・D14:コクシジウム症負荷=それぞれ75,000、25,000、及び50,000のE.アセルブリナ、E.マキシマ、及びE.テネラ
・D20:糞便物(ケージ毎に混合)中の接合子嚢数(oocysts count)
腸病変スコアリング(5羽の鳥/ケージ)
結果
Claims (22)
- 少なくとも1種のカンジダ種からの菌体壁多糖及び少なくとも1種の異なる酵母種からの菌体壁多糖を含む組成物であって、
前記少なくとも1種のカンジダ種からの菌体壁多糖及び前記少なくとも1種の異なる酵母種からの菌体壁多糖は、キチン、マンナンオリゴ糖、ベータ1,3グルカン及びベータ1,6グルカンであり、その量が、前記組成物の総重量を基準として30~60重量%である組成物。 - 前記少なくとも1種のカンジダ種からの菌体壁多糖の量が、前記組成物中の菌体壁多糖の総重量を基準として10~50乾燥重量%である、請求項1に記載の組成物。
- 前記少なくとも1種のカンジダ種からの菌体壁多糖の量が、前記組成物中の菌体壁多糖の総重量を基準として10~15乾燥重量%である、請求項1又は2に記載の組成物。
- 前記少なくとも1種のカンジダ種からの菌体壁多糖の量が、前記組成物中の菌体壁多糖の総重量を基準として少なくとも10、15、20、25、30、35、40、45又は50乾燥重量%である、請求項2に記載の組成物。
- 前記少なくとも1種のカンジダ種からの菌体壁多糖の量が、前記組成物中の菌体壁多糖の総重量を基準として少なくとも10、11、12、13、14又は15乾燥重量%である、請求項3に記載の組成物。
- 前記少なくとも1種のカンジダ種からの菌体壁多糖及び前記少なくとも1種の異なる酵母種からの菌体壁多糖の量が、前記組成物の総重量を基準として少なくとも30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50、51、52、53、54、55、56、57、58、59又は60重量%である、請求項1~5のいずれか1項に記載の組成物。
- 前記少なくとも1種のカンジダ種からの菌体壁多糖の量が、前記組成物中の菌体壁多糖の総重量を基準として10~50乾燥重量%であり、かつ、前記少なくとも1種のカンジダ種からの菌体壁多糖及び前記少なくとも1種の異なる酵母種からの菌体壁多糖の量が、前記組成物の総重量を基準として30~60重量%である、請求項1に記載の組成物。
- 前記少なくとも1種のカンジダ種からの菌体壁多糖の量が、前記組成物中の菌体壁多糖の総重量を基準として少なくとも10、15、20、25、30、35、40、45又は50乾燥重量%であり、かつ、前記少なくとも1種のカンジダ種からの菌体壁多糖及び前記少なくとも1種の異なる酵母種からの菌体壁多糖の量が、前記組成物の総重量を基準として30~60重量%である、請求項1に記載の組成物。
- 前記少なくとも1種のカンジダ種からの菌体壁多糖の量が、前記組成物中の菌体壁多糖の総重量を基準として10~50乾燥重量%であり、かつ、前記少なくとも1種のカンジダ種からの菌体壁多糖及び前記少なくとも1種の異なる酵母種からの菌体壁多糖の量が、前記組成物の総重量を基準として少なくとも30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50、51、52、53、54、55、56、57、58、59又は60重量%である、請求項1に記載の組成物。
- 前記少なくとも1種のカンジダ種からの菌体壁多糖の量が、前記組成物中の菌体壁多糖の総重量を基準として少なくとも10、15、20、25、30、35、40、45又は50乾燥重量%であり、かつ、前記少なくとも1種のカンジダ種からの菌体壁多糖及び前記少なくとも1種の異なる酵母種からの菌体壁多糖の量が、前記組成物の総重量を基準として少なくとも30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50、51、52、53、54、55、56、57、58、59又は60重量%である、請求項1に記載の組成物。
- 前記少なくとも1種のカンジダ種がカンジダ・ユチリスである、請求項1~10のいずれか1項に記載の組成物。
- 前記少なくとも1種の異なる酵母種からの菌体壁多糖が、サッカロマイセス種、ハンセニアスポラ種、ハンゼヌラ種、クルイベロマイセス種、メチニコビア種、ピキア種、スターメレラ種及びトルラスポラ種又はこれらの混合種由来である、請求項1~11のいずれか1項に記載の組成物。
- 動物において免疫応答を調節及び/又は刺激するのに使用するための、請求項1~12のいずれか1項に記載の組成物。
- 動物の腸管の健康、腸管の完全性及び腸管の形態を改善するのに使用するための、請求項1~12のいずれか1項に記載の組成物。
- 動物の抗炎症応答を刺激するのに使用するための、請求項1~12のいずれか1項に記載の組成物。
- 飼育動物の成長成績パラメータ及び飼料要求率を改善するのに使用するための、請求項1~12のいずれか1項に記載の組成物。
- 飼育動物の罹患率、特には抗生物質による治療及び死亡率を低減するのに使用するための、請求項1~12のいずれか1項に記載の組成物。
- 飼育動物の死亡率を低下させるのに使用するための、請求項1~12のいずれか1項に記載の組成物。
- 動物の下痢を減少させるのに使用するための、請求項1~12のいずれか1項に記載の組成物。
- 腸管病原体に対する感受性を低下させるのに使用するための、請求項1~12のいずれか1項に記載の組成物。
- 寄生虫侵襲及び関連疾患に対する動物の感受性を低下させるのに使用するための、請求項1~12のいずれか1項に記載の組成物。
- 水生動物の皮膚粘液の産生を改善するのに使用するための、請求項1~12のいずれか1項に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021119917A JP7291749B2 (ja) | 2015-07-09 | 2021-07-20 | ヒト及び/又は動物における免疫応答を調節及び/又は刺激するための組成物及び方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15176029.5A EP3138573A1 (en) | 2015-07-09 | 2015-07-09 | Compositions and methods for stimulating immune responses in human and/or animal |
EP15176029.5 | 2015-07-09 | ||
PCT/EP2016/066446 WO2017005936A1 (en) | 2015-07-09 | 2016-07-11 | Compositions and methods for modulating and/or stimulating immune responses in human and/or animal |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021119917A Division JP7291749B2 (ja) | 2015-07-09 | 2021-07-20 | ヒト及び/又は動物における免疫応答を調節及び/又は刺激するための組成物及び方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018522001A JP2018522001A (ja) | 2018-08-09 |
JP7252758B2 true JP7252758B2 (ja) | 2023-04-05 |
Family
ID=53776303
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018500382A Active JP7252758B2 (ja) | 2015-07-09 | 2016-07-11 | ヒト及び/又は動物における免疫応答を調節及び/又は刺激するための組成物及び方法 |
JP2021119917A Active JP7291749B2 (ja) | 2015-07-09 | 2021-07-20 | ヒト及び/又は動物における免疫応答を調節及び/又は刺激するための組成物及び方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021119917A Active JP7291749B2 (ja) | 2015-07-09 | 2021-07-20 | ヒト及び/又は動物における免疫応答を調節及び/又は刺激するための組成物及び方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US11338023B2 (ja) |
EP (2) | EP3138573A1 (ja) |
JP (2) | JP7252758B2 (ja) |
CN (1) | CN107847536A (ja) |
AU (1) | AU2016289523B2 (ja) |
BR (1) | BR112018000102B1 (ja) |
CA (1) | CA2990530A1 (ja) |
CL (1) | CL2017003442A1 (ja) |
DK (1) | DK3319621T3 (ja) |
ES (1) | ES2953462T3 (ja) |
HU (1) | HUE063641T2 (ja) |
PL (1) | PL3319621T3 (ja) |
WO (1) | WO2017005936A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020180424A1 (en) | 2019-03-04 | 2020-09-10 | Iocurrents, Inc. | Data compression and communication using machine learning |
WO2023220275A1 (en) * | 2022-05-12 | 2023-11-16 | Can Technologies, Inc. | Compositions and methods for the treatment and prevention of coccidiosis infection |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080008767A1 (en) | 2004-06-25 | 2008-01-10 | Cepta Duffy | Methods And Compositions For Controlling Parasitic Infections Of Animals |
JP2009203160A (ja) | 2006-05-25 | 2009-09-10 | Saihatsu Ko | 抗ウィルス及び抗菌剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506210A (en) * | 1988-08-19 | 1996-04-09 | The Australian National University | Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs |
CA2040374C (en) * | 1990-07-06 | 1998-06-16 | Gunnar Rorstad | Process for enhancing the resistance of aquatic animals to disease |
FR2726284B1 (fr) | 1994-10-31 | 1996-12-27 | Inst Oenologie | Produit biologique pour la stabilisation physico-chimique d'un vin |
US6214337B1 (en) * | 1995-04-18 | 2001-04-10 | Biotec Asa | Animal feeds comprising yeast glucan |
US20030235569A1 (en) * | 2002-06-18 | 2003-12-25 | Ling Yuk Cheung | Feed additives for chickens |
AU2008240794B2 (en) | 2007-04-20 | 2013-10-10 | Rymco International Ag | Peptide mixture as wine stabiliser |
CN102228138B (zh) * | 2011-06-04 | 2013-01-16 | 内蒙古农业大学 | 一种反刍动物微生态添加剂及其制备工艺 |
-
2015
- 2015-07-09 EP EP15176029.5A patent/EP3138573A1/en not_active Withdrawn
-
2016
- 2016-07-11 CN CN201680040529.3A patent/CN107847536A/zh active Pending
- 2016-07-11 WO PCT/EP2016/066446 patent/WO2017005936A1/en active Application Filing
- 2016-07-11 US US15/741,832 patent/US11338023B2/en active Active
- 2016-07-11 BR BR112018000102-3A patent/BR112018000102B1/pt active IP Right Grant
- 2016-07-11 CA CA2990530A patent/CA2990530A1/en active Pending
- 2016-07-11 PL PL16738145.8T patent/PL3319621T3/pl unknown
- 2016-07-11 DK DK16738145.8T patent/DK3319621T3/da active
- 2016-07-11 HU HUE16738145A patent/HUE063641T2/hu unknown
- 2016-07-11 ES ES16738145T patent/ES2953462T3/es active Active
- 2016-07-11 EP EP16738145.8A patent/EP3319621B1/en active Active
- 2016-07-11 JP JP2018500382A patent/JP7252758B2/ja active Active
- 2016-07-11 AU AU2016289523A patent/AU2016289523B2/en active Active
-
2017
- 2017-12-28 CL CL2017003442A patent/CL2017003442A1/es unknown
-
2021
- 2021-07-20 JP JP2021119917A patent/JP7291749B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080008767A1 (en) | 2004-06-25 | 2008-01-10 | Cepta Duffy | Methods And Compositions For Controlling Parasitic Infections Of Animals |
JP2009203160A (ja) | 2006-05-25 | 2009-09-10 | Saihatsu Ko | 抗ウィルス及び抗菌剤 |
Non-Patent Citations (1)
Title |
---|
PLoS ONE,2012年,Volume 7, Issue 7, e40648,https://doi.org/10.1371/journal.pone.0040648 |
Also Published As
Publication number | Publication date |
---|---|
EP3319621A1 (en) | 2018-05-16 |
JP2021183608A (ja) | 2021-12-02 |
EP3319621B1 (en) | 2023-06-07 |
CL2017003442A1 (es) | 2018-07-13 |
US11338023B2 (en) | 2022-05-24 |
DK3319621T3 (da) | 2023-08-21 |
AU2016289523A1 (en) | 2018-01-18 |
WO2017005936A9 (en) | 2017-03-09 |
CA2990530A1 (en) | 2017-01-12 |
JP7291749B2 (ja) | 2023-06-15 |
CN107847536A (zh) | 2018-03-27 |
AU2016289523B2 (en) | 2022-07-14 |
PL3319621T3 (pl) | 2023-10-09 |
BR112018000102B1 (pt) | 2021-10-05 |
HUE063641T2 (hu) | 2024-01-28 |
EP3138573A1 (en) | 2017-03-08 |
ES2953462T3 (es) | 2023-11-13 |
BR112018000102A2 (pt) | 2018-09-04 |
WO2017005936A1 (en) | 2017-01-12 |
US20180207248A1 (en) | 2018-07-26 |
JP2018522001A (ja) | 2018-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chand et al. | Anticoccidial effect of mananoligosacharide against experimentally induced coccidiosis in broiler | |
Hoseinifar et al. | Prebiotics and fish immune response: a review of current knowledge and future perspectives | |
Bridle et al. | The effect of β‐glucan administration on macrophage respiratory burst activity and Atlantic salmon, Salmo salar L., challenged with amoebic gill disease–evidence of inherent resistance | |
CA2999247C (en) | Compositions and combinations for use as food supplements for animals | |
Skjermo et al. | Evaluation of β-(1→ 3, 1→ 6)-glucans and High-M alginate used as immunostimulatory dietary supplement during first feeding and weaning of Atlantic cod (Gadus morhua L.) | |
JP7291749B2 (ja) | ヒト及び/又は動物における免疫応答を調節及び/又は刺激するための組成物及び方法 | |
Kunttu et al. | The efficacy of two immunostimulants against Flavobacterium columnare infection in juvenile rainbow trout (Oncorhynchus mykiss) | |
WO2018049243A1 (en) | Feed additive comprising allicin | |
EP2432478B1 (en) | The improvement of gastrointestinal health, immunity and performance by dietary intervention | |
JP4584577B2 (ja) | コクシジウムの制御のための方法および組成物 | |
Palić et al. | Immunomodulatory effects of β-glucan on neutrophil function in fathead minnows (Pimephales promelas Rafinesque, 1820) | |
US20220184159A1 (en) | Method of boosting innate immunity | |
Elmusharaf et al. | Effect of a mannanoligosaccharide preparation on Eimeria tenella infection in broiler chickens | |
TWI656872B (zh) | 甲基鹽黴素於豬飼料中之抗病毒效果 | |
Amer et al. | Avian gastric yeast (AGY) infection (macrorhabdiosis or megabacteriosis). | |
Allinson et al. | Effect of herbal supplement on growth response and faecal egg counts of cockerels | |
KR102208837B1 (ko) | 메틸 갈레이트 및 플로로퀴놀론 계열 항균제를 포함하는 박테리아의 장 부착, 침입 억제, 또는 항생제 내성 억제용 조성물 | |
US20220400703A1 (en) | Formulations for treatment of vibrio infections | |
BR112020025226A2 (pt) | Composição antiparasitária, produto alimentar e uso da composição antiparasitária | |
Abudabos | Naila Chand, Hassan Faheem, Rifat Ullah Khan, Muhammad Subhan Qureshi, Ibrahim A. Alhidary & | |
El Moghazy et al. | EFFECT OF ROSEMARY, BASIL AND GARLIC OILS AS NATURAL GROWTH PROMOTERS IN BROILER CHICKS | |
ABD EL-GHANY et al. | COMPARATIVE STUDY ON THE EFFICACY OF A PROBIOTIC AND DIFFERRENT ANTICOCCIDIAL DRUGS AGAINST EIMERIA TENELLA INFECTION IN BROILER CHICKENS | |
Cuesta | Prebiotics and fish immune response: a review of current knowledge and future perspectives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190515 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200526 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200819 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201125 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210720 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210720 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20210803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210824 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210928 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20211004 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20211029 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20211108 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220712 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20230207 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20230307 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20230307 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230324 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7252758 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |